185 related articles for article (PubMed ID: 33538176)
1. Metaplastic breast cancer: an old histotype but a current therapeutic problem.
Gadaleta-Caldarola G; Nenna R; Lanotte L; Doronzo A; Gadaleta-Caldarola A; Roma I; Lombardi L; Infusino S
Future Oncol; 2021 Mar; 17(8):955-963. PubMed ID: 33538176
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of an Immune Checkpoint (CD155) in Breast Cancer Associated with Prognostic Significance and Exhausted Tumor-Infiltrating Lymphocytes: A Cohort Study.
Li YC; Zhou Q; Song QK; Wang RB; Lyu S; Guan X; Zhao YJ; Wu JP
J Immunol Res; 2020; 2020():3948928. PubMed ID: 32411795
[TBL] [Abstract][Full Text] [Related]
3. Emerging immune gene signatures as prognostic or predictive biomarkers in breast cancer.
Kwon MJ
Arch Pharm Res; 2019 Nov; 42(11):947-961. PubMed ID: 31707598
[TBL] [Abstract][Full Text] [Related]
4. Triple‑negative breast cancer therapy: Current and future perspectives (Review).
Won KA; Spruck C
Int J Oncol; 2020 Dec; 57(6):1245-1261. PubMed ID: 33174058
[TBL] [Abstract][Full Text] [Related]
5. Predicting the immune landscape of invasive breast carcinoma based on the novel signature of immune-related lncRNA.
Shen S; Chen X; Hu X; Huo J; Luo L; Zhou X
Cancer Med; 2021 Sep; 10(18):6561-6575. PubMed ID: 34378851
[TBL] [Abstract][Full Text] [Related]
6. Determining Factors in the Therapeutic Success of Checkpoint Immunotherapies against PD-L1 in Breast Cancer: A Focus on Epithelial-Mesenchymal Transition Activation.
Segovia-Mendoza M; Romero-Garcia S; Lemini C; Prado-Garcia H
J Immunol Res; 2021; 2021():6668573. PubMed ID: 33506060
[TBL] [Abstract][Full Text] [Related]
7. PD-L1 Acts as a Promising Immune Marker to Predict the Response to Neoadjuvant Chemotherapy in Breast Cancer Patients.
Du Q; Che J; Jiang X; Li L; Luo X; Li Q
Clin Breast Cancer; 2020 Feb; 20(1):e99-e111. PubMed ID: 31521537
[TBL] [Abstract][Full Text] [Related]
8. PD‑L1/PD‑1 blockade in breast cancer: The immunotherapy era (Review).
Li CJ; Lin LT; Hou MF; Chu PY
Oncol Rep; 2021 Jan; 45(1):5-12. PubMed ID: 33416128
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic landscape of metaplastic breast cancer.
Tray N; Taff J; Adams S
Cancer Treat Rev; 2019 Sep; 79():101888. PubMed ID: 31491663
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathologic Factors Associated With Response to Neoadjuvant Anti-HER2-Directed Chemotherapy in HER2-Positive Breast Cancer.
Meisel JL; Zhao J; Suo A; Zhang C; Wei Z; Taylor C; Aneja R; Krishnamurti U; Li Z; Nahta R; O'Regan R; Li X
Clin Breast Cancer; 2020 Feb; 20(1):19-24. PubMed ID: 31806448
[TBL] [Abstract][Full Text] [Related]
11. A Systematic Literature Review of the Prognostic and Predictive Value of PIK3CA Mutations in HR
Mollon LE; Anderson EJ; Dean JL; Warholak TL; Aizer A; Platt EA; Tang DH; Davis LE
Clin Breast Cancer; 2020 Jun; 20(3):e232-e243. PubMed ID: 32234362
[TBL] [Abstract][Full Text] [Related]
12. Does adjuvant therapy reduce postmetastatic survival?
Fink MK
Ann Oncol; 2019 Aug; 30(8):1184-1188. PubMed ID: 31095301
[No Abstract] [Full Text] [Related]
13. Metformin in breast cancer: preclinical and clinical evidence.
De A; Kuppusamy G
Curr Probl Cancer; 2020 Feb; 44(1):100488. PubMed ID: 31235186
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint inhibitors for triple-negative breast cancer: From immunological mechanisms to clinical evidence.
Farshbafnadi M; Pastaki Khoshbin A; Rezaei N
Int Immunopharmacol; 2021 Sep; 98():107876. PubMed ID: 34146865
[TBL] [Abstract][Full Text] [Related]
15. Early progression of breast cancer during neoadjuvant chemotherapy may predict poorer prognoses.
Myller S; Ipatti P; Jääskeläinen A; Haapasaari KM; Jukkola A; Karihtala P
Acta Oncol; 2020 Sep; 59(9):1036-1042. PubMed ID: 32394761
[No Abstract] [Full Text] [Related]
16. Metaplastic carcinoma of the breast: Prognosis and response to systemic treatment in metastatic disease.
Takala S; Heikkilä P; Nevanlinna H; Blomqvist C; Mattson J
Breast J; 2019 May; 25(3):418-424. PubMed ID: 30925636
[TBL] [Abstract][Full Text] [Related]
17. Rac1 activation in human breast carcinoma as a prognostic factor associated with therapeutic resistance.
Yamaguchi M; Takagi K; Sato A; Miki Y; Miyashita M; Sasano H; Suzuki T
Breast Cancer; 2020 Sep; 27(5):919-928. PubMed ID: 32314182
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
[TBL] [Abstract][Full Text] [Related]
19. Trastuzumab Emtansine: Mechanisms of Action and Resistance, Clinical Progress, and Beyond.
García-Alonso S; Ocaña A; Pandiella A
Trends Cancer; 2020 Feb; 6(2):130-146. PubMed ID: 32061303
[TBL] [Abstract][Full Text] [Related]
20. Metaplastic breast cancer: Prognostic and therapeutic considerations.
Corso G; Frassoni S; Girardi A; De Camilli E; Montagna E; Intra M; Bottiglieri L; Margherita De Scalzi A; Fanianos DM; Magnoni F; Invento A; Toesca A; Conforti F; Bagnardi V; Viale G; Colleoni MA; Veronesi P
J Surg Oncol; 2021 Jan; 123(1):61-70. PubMed ID: 33047318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
